Company touted Kisqali's "replacement power" as another blockbuster faces generic competition and expressed optimism about ...

For $1.8 million upfront and additional contingent and milestone payments, I-Mab gains full rights to givastomig's parental antibody.

In a final draft guidance, the committee recommended the treatment for HR-positive HER2-negative early breast cancer patients, regardless of lymph node involvement.

The company will pause several gene therapy development programs, for which it intends to seek partners and other strategic alternatives.

A study published by Caris showed that certain tumor types had very low or no HER2 overexpression, which has implications for biomarker testing strategies.

The revenue for the cell therapy Carvykti and the EGFR-targeted lung cancer duo Rybrevant-Lazcluze contributed to double digit gains in oncology drug sales.

The company hopes to commercialize its tumor profiling assay after it secures $10 million via a share purchase agreement.

Debiopharm will take over development of the PKMYT1 inhibitor and advance it in combination with its WEE1 inhibitor in the MYTHIC trial.

The participating regions are home to 84 percent of sickle cell Medicaid patients who could gain access to gene therapies under outcomes-based agreements.

The privately funded basket trial makes good on its aim to enroll underrepresented groups amid a DEI-hostile federal funding ...

The company, which spun out of a Korean institute, said its test has been listed at 10 leading hospitals and academic centers.

While NICE recommended the drug for patients with at least one F508del mutation, Vertex struck a reimbursement deal with NHS England for a broader population.